Tags

Type your tag names separated by a space and hit enter

MRI versus breast-specific gamma imaging (BSGI) in newly diagnosed ductal cell carcinoma-in-situ: a prospective head-to-head trial.
Ann Surg Oncol. 2012 Jan; 19(1):249-52.AS

Abstract

BACKGROUND

Mammography remains the standard imaging technique for the diagnosis of ductal carcinoma-in-situ (DCIS). Functional breast imaging, including breast magnetic resonance imaging (MRI), has known limitations in evaluating DCIS. To date, there are limited data on the utility of breast-specific gamma imaging (BSGI) in DCIS. We sought to prospectively compare the sensitivity of BSGI to MRI in newly diagnosed DCIS patients.

METHODS

Patients with newly diagnosed DCIS from June 1, 2009, through May 31, 2010, underwent a protocol with both breast MRI and BSGI. Each imaging study was read by a separate dedicated breast radiologist. Patients were excluded if excisional biopsy was performed for diagnosis, if their MRI was performed at an outside facility, or if final pathology revealed invasive carcinoma.

RESULTS

There were 18 patients enrolled onto the study that had both MRI and BSGI for newly diagnosed DCIS. The sensitivity for MRI was 94% and for BSGI was 89% (P > 0.5, NS). There was one index tumor not seen on either MRI or BSGI, and one index tumor seen on MRI but not visualized on BSGI.

DISCUSSION

Although BSGI has previously been shown to be as sensitive as MRI for detecting known invasive breast carcinoma, this study shows that BSGI is equally as sensitive as MRI at detecting newly diagnosed DCIS. As a result of the limited number of patients enrolled onto the study, larger prospective studies need to be performed to determine the true sensitivity and specificity of BSGI.

Authors+Show Affiliations

Department of Surgery, Beth Israel Medical Center, New York, NY, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article

Language

eng

PubMed ID

21739318

Citation

Keto, Jessica L., et al. "MRI Versus Breast-specific Gamma Imaging (BSGI) in Newly Diagnosed Ductal Cell Carcinoma-in-situ: a Prospective Head-to-head Trial." Annals of Surgical Oncology, vol. 19, no. 1, 2012, pp. 249-52.
Keto JL, Kirstein L, Sanchez DP, et al. MRI versus breast-specific gamma imaging (BSGI) in newly diagnosed ductal cell carcinoma-in-situ: a prospective head-to-head trial. Ann Surg Oncol. 2012;19(1):249-52.
Keto, J. L., Kirstein, L., Sanchez, D. P., Fulop, T., McPartland, L., Cohen, I., & Boolbol, S. K. (2012). MRI versus breast-specific gamma imaging (BSGI) in newly diagnosed ductal cell carcinoma-in-situ: a prospective head-to-head trial. Annals of Surgical Oncology, 19(1), 249-52. https://doi.org/10.1245/s10434-011-1848-3
Keto JL, et al. MRI Versus Breast-specific Gamma Imaging (BSGI) in Newly Diagnosed Ductal Cell Carcinoma-in-situ: a Prospective Head-to-head Trial. Ann Surg Oncol. 2012;19(1):249-52. PubMed PMID: 21739318.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - MRI versus breast-specific gamma imaging (BSGI) in newly diagnosed ductal cell carcinoma-in-situ: a prospective head-to-head trial. AU - Keto,Jessica L, AU - Kirstein,Laurie, AU - Sanchez,Diana P, AU - Fulop,Tamara, AU - McPartland,Laura, AU - Cohen,Ilona, AU - Boolbol,Susan K, Y1 - 2011/07/08/ PY - 2011/03/14/received PY - 2011/7/9/entrez PY - 2011/7/9/pubmed PY - 2012/5/18/medline SP - 249 EP - 52 JF - Annals of surgical oncology JO - Ann Surg Oncol VL - 19 IS - 1 N2 - BACKGROUND: Mammography remains the standard imaging technique for the diagnosis of ductal carcinoma-in-situ (DCIS). Functional breast imaging, including breast magnetic resonance imaging (MRI), has known limitations in evaluating DCIS. To date, there are limited data on the utility of breast-specific gamma imaging (BSGI) in DCIS. We sought to prospectively compare the sensitivity of BSGI to MRI in newly diagnosed DCIS patients. METHODS: Patients with newly diagnosed DCIS from June 1, 2009, through May 31, 2010, underwent a protocol with both breast MRI and BSGI. Each imaging study was read by a separate dedicated breast radiologist. Patients were excluded if excisional biopsy was performed for diagnosis, if their MRI was performed at an outside facility, or if final pathology revealed invasive carcinoma. RESULTS: There were 18 patients enrolled onto the study that had both MRI and BSGI for newly diagnosed DCIS. The sensitivity for MRI was 94% and for BSGI was 89% (P > 0.5, NS). There was one index tumor not seen on either MRI or BSGI, and one index tumor seen on MRI but not visualized on BSGI. DISCUSSION: Although BSGI has previously been shown to be as sensitive as MRI for detecting known invasive breast carcinoma, this study shows that BSGI is equally as sensitive as MRI at detecting newly diagnosed DCIS. As a result of the limited number of patients enrolled onto the study, larger prospective studies need to be performed to determine the true sensitivity and specificity of BSGI. SN - 1534-4681 UR - https://www.unboundmedicine.com/medline/citation/21739318/MRI_versus_breast_specific_gamma_imaging__BSGI__in_newly_diagnosed_ductal_cell_carcinoma_in_situ:_a_prospective_head_to_head_trial_ L2 - https://dx.doi.org/10.1245/s10434-011-1848-3 DB - PRIME DP - Unbound Medicine ER -